UPPSALA, SWEDEN / ACCESSWIRE / October 30, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) invites investors, analysts, and media to a webcast presentation of the third quarter report for 2024 on November 6, 15:00 CET. The report will be published during the morning of the same day.
The presentation will be held by Philip Siberg, CEO of Senzime, and after the presentation, there will be a Q&A session moderated by Klas Palin, analyst at Carnegie Investment Bank. The presentation will be held in English.
Date and time: Wednesday, November 6, 15:00-15:30 CET
Questions to moderator can be sent by email in advance to klas.palin@carnegie.se before 12:00 CET on Nov 6.
The presentation will be accessible at Senzime’s website https://www.senzime.com/investors
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime’s TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime’s products are commercialized in over 30 countries including direct sales teams in US and Germany.
Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at senzime.com.
Attachments
Invitation to presentation of Senzime’s third quarter 2024 report
SOURCE: Senzime
View the original press release on accesswire.com
IRVINE, Calif.--(BUSINESS WIRE)--#RespiratoryCare--Nihon Kohden, a global leader in medical technology, today announced the introduction of…
APTA advocacy leads to impactful policy wins that will reduce administrative burden, improve access, and…
NEWTON, Mass., Nov. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical…
SPOKANE, Wash. and NEW YORK, Nov. 1, 2024 /PRNewswire/ -- Gestalt, a leader in digital pathology…
SALT LAKE CITY and OXFORD, United Kingdom, Nov. 1, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL),…
With the upcoming election, individuals must brace for potential economic shifts and policy changes that…